Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | BCL6 | P41182 | 7/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761489 | 0.80 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL30745333 | 0.74 | CNR2 (0.56) | CNR2CNR1BCL6NPC1GAA | |
| SCHEMBL739986 | 0.72 | CNR2 (0.73) | CNR2CNR1NPC1 | |
| SCHEMBL30904706 | 0.70 | CNR1 (0.53) | CNR2CNR1BCL6NPC1GAA | |
| SCHEMBL31357282 | 0.69 | CNR2 (0.52) | CNR2CNR1BCL6NPC1GAA | |
| SCHEMBL20569640 | 0.66 | CNR2 (0.51) | CNR2CNR1NPC1GAA | |
| SCHEMBL762192 | 0.64 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL762197 | 0.63 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL740426 | 0.63 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL739509 | 0.62 | CNR2 (0.71) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885SLC6A2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.